Fig. 4.

Gene expression profiles in saracatinib- and oxaliplatin-resistant HCC revealed upregulation of ABCG1 and activation of Wnt signaling-associated proteins. Gene expression profiles were compared between wild-type MHCC97L and MHCC97L-Src (a) and between MHCC97L and MHCC97L-Src (b). (c) A total of 458 genes were found to be altered in both sets of cells. (d) These genes were related to cell division, growth, angiogenesis, adhesion, and metabolic processes, and KEGG pathway analysis was performed on these altered genes. (e) The altered genes related to drug resistance were partly selected. (f) Immunoblotting was used to determine the protein expression of the genes that were altered most dramatically between the wild-type and drug-resistant cell lines. (g) Immunoblotting confirmed the upregulation of ABCG1 after combination treatment with oxaliplatinor and saracatinib. (h) Immunohisochemotherapy verified that the expression of ABCG1 was significantly upregulated after the treatment with oxaliplatinor or saracatinib and combination treatment in subcutaneous xenografts tissues